Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of androgen deprivation therapy on PSMA expression in prostate cancer
2017-002345-29Phase 2Completed
- Sponsor
- Turku University Hospital
- Start
- Oct 2018
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of relugolix in prostate cancer (PCa), sponsored by Turku University Hospital. Primary endpoints: Time course of PSMA expression after GnRH-antagonist initiation and Relationship between testosterone decline and PSMA expression. Started Oct 2018; status: completed.
02
Drugs
relugolix
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2017-002345-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002345-29.